FDA Clearance Tracker · P170043-S020
iStent inject Trabecular MicroBypass System
Last checked: Nov 20, 2026Latest source record: Jan 13, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Jan 13, 2025
Approved
Time to decision
179 days
Received Jul 18, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P170043-S020
- Device name
- iStent inject Trabecular MicroBypass System
- Applicant
- Glaukos Corporation
- Applicant location
- San Clemente, CA
- Received
- Jul 18, 2024
- Decided
- Jan 13, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P170043
Device type
- Device type
- Intraocular pressure lowering implant (OGO)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Request for approval of labeling changes made to the Directions for Use and Package Insert.
Source documents
Other decisions for Glaukos Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K220032 · Decided Aug 2, 2022 · 209 days after receipt
Device type: Implant, Eye Valve (KYF) · Ophthalmology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.